The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab
Preetesh Jain, Graciela M Nogueras Gonzalez, Rashmi Kanagal-Shamanna, Uri Rozovski, Nawid Sarwari, Constantine Tam, William G Wierda, Philip A Thompson, Nitin Jain, Rajyalakshmi Luthra, Andres Quesada, Gabriela Sanchez-Petitto, Alessandra Ferrajoli, Jan Burger, Hagop Kantarjian, Jorge Cortes, Susan O'Brien, Michael J Keating, Zeev Estrov
British Journal of Haematology | WILEY | Published : 2018
Awarded by NIH/NCI
Awarded by NCI
This study was supported in part by the NIH/NCI award number P30CA016672 and by NCI award number P01CA049639. We thank Chalaire Dawn from scientific publications department of MDACC, for editing the manuscript.